CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Auriga Laboratories Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Auriga Laboratories Inc.
5284 Adolfo Road
Phone: (805) 437-7200p:805 437-7200 Camarillo, CA  93012  United States
This company is no longer actively traded on any major stock exchange.
Business Summary
Auriga Laboratories, Inc. is a specialty pharmaceutical company engaged in the commercialization, licensing, and development of prescription pharmaceutical products. The Company’s products are focused in the respiratory, dermatology central nervous system (CNS) and anti-infective therapeutic categories and are marketed to primary care physicians, pediatricians, dermatologists, urologists, psychiatrists, and rheumatologists. On December 3, 2007, the Company announced its acquisition of a license from Outlook Pharmaceuticals, Inc., to make, distribute, commercialize, market and sell in the United States a new product, Liquadd, indicated for the treatment of attention deficit hyperactivity disorder. On January 7, 2008, the Company announced its acquisition from Middlebrook Pharmaceuticals, Inc. of the right to co-promote Keflex 750 milligrams capsules (cephalexin capsules, USP), to primary care physicians in the United States.
(Source: 10KSB)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/200812/31/2007YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer, Director Frank R.Greico 50 6/16/2008 9/1/2007
Corporate Secretary Sharyn G.Alcaraz 40 1/23/2008 11/1/2007

Business Names
Business Name
ARGA
Auriga Laboratories Inc.
Multi Link Telecommunications, Inc.

General Information
Outstanding Shares: 79,536,557 (As of 5/12/2008)
Shareholders: 378
Stock Exchange: OTC
Federal Tax Id: 841334687


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023